With this revised deal, Anacor has decided to give an option to GSK for extending its rights for the bacterial enzyme targeting LeuRS, as well as to add new programs for tuberculosis (TB) and malaria using Anacor’s boron chemistry platform.
As per the changes, GSK is now responsible to pay a sum of $5m as an upfront payment to Anacor as well as additional milestones and research funding of up to $11.3m by the end of 2012.
Anacor is also entitled to obtain additional milestones and royalties on future sales of resulting products from GSK.